We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FPE3:XETRFUCHS SE Pref Registered Shs Analysis

Data as of 2026-05-25 - not real-time

€37.54

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Fuchs SE trades at €37.54, slightly above its DCF‑derived fair value of €36.51, yet still offers roughly a 25% upside to the median analyst target of €47. Technical momentum is neutral – the price sits between the 20‑day SMA (€37.98) and 50‑day SMA (€36.92), the RSI is near 50, and a bearish MACD histogram signals short‑term pressure, compounded by a decreasing volume trend. Fundamentally, the company posts a modest 1.1% revenue growth, solid profitability (gross margin 35%, operating margin 13%, ROE 15.7%) and a healthy free cash flow of €335 M, supporting a 3.28% dividend yield with a 52% payout ratio. Analysts are bullish, with a consensus “buy” and a forward P/E of 14.1, indicating the stock is priced fairly relative to earnings expectations. The specialty chemicals sector is cyclical, but Fuchs benefits from diversified geographic exposure and a resilient demand base, making the share attractive for income‑focused investors while offering upside potential if earnings improve.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Neutral price relative to short‑term moving averages
  • Bearish MACD histogram indicating recent momentum weakness
  • Decreasing trading volume reducing short‑term liquidity

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Upside potential of ~25% to analyst median target
  • Strong dividend yield with sustainable payout
  • Improving forward EPS and solid cash flow generation

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Diversified global customer base reducing geographic concentration risk
  • Stable profitability in a specialty chemicals niche
  • Consistent dividend policy supporting long‑term shareholder returns

Key Metrics & Analysis

Financial Health

Revenue Growth1.10%
Profit Margin8.90%
P/E Ratio16.8
ROE15.71%
ROA9.98%
Debt/Equity6.42
P/B Ratio2.4
Op. Cash Flow€441.0M
Free Cash Flow€335.5M

Technical Analysis

TrendNeutral
RSI50.0
Support€36.42
Resistance€41.40
MA 20€37.98
MA 50€36.92
MA 200€38.24
MACDBearish
VolumeDecreasing
Fear & Greed Index91.8

Valuation

Fair Value€36.51
Target Price€46.89
Upside/Downside24.91%
GradeFair
TypeValue
Dividend Yield3.28%

Risk Assessment

Beta0.01
Volatility35.60%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.